ASND vs EVO
Ascendis Pharma A/S and Evotec SE, side by side — 6 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ASND | EVO |
|---|---|---|
| Revenue | €720.1M | €797.0M |
| Net income | €-228.0M | €-196.1M |
| Gross margin | 86.8% | 14.4% |
| Net margin | −31.7% | −24.6% |
| Return on equity | — | −18.9% |
| Diluted EPS | −€3.76 | −€1.11 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | €-469.8M | €-99.2M |
| Equity | — | €952.5M |
| Net debt / equity | — | −0.02× |
| Current ratio | 1.04× | 1.98× |
| Revenue CAGR 5y | 153.0% | 12.3% |
| Profit CAGR 5y | — | — |
ASND and EVO book revenue within 15% of each other, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
6 years side by side
| Fiscal year | ASND | EVO |
|---|---|---|
| FY2024 | €363.6M | €797.0M |
| FY2023 | €266.7M | €781.4M |
| FY2022 | €51.2M | €751.4M |
| FY2021 | €7.8M | €618.0M |
| FY2020 | €7.0M | €500.9M |
| FY2019 | €13.4M | €446.4M |
Net income by year
Bottom line
| Fiscal year | ASND | EVO |
|---|---|---|
| FY2024 | €-378.1M | €-196.1M |
| FY2023 | €-481.4M | €-83.9M |
| FY2022 | €-583.2M | €-175.7M |
| FY2021 | €-383.6M | €215.5M |
| FY2020 | €-419.0M | €6.3M |
| FY2019 | €-218.0M | €38.2M |
Advertisement
AdSense · Rectangle 336×280